Clincal trial progress/Nov. 7 Barcelona presentation: I agree with Ziggy and Josh. Everyone is pondering about this presentation, of course. However, let's face it folks. S. Macfarlane will be there. He will in all probability be the lead presenter. After all, he is running the trials. He said recently -- this summer -- about the Anavex trials that he has never in his life time seen anything like this in referring to the Anavex trial results he is conducting. This came straight from the "horse's mouth". It would be a sudden and stunning reversal indeed to, about 3 months later, plan to report that this clinical trial is a flop. Therefore, I ask again, primarily for the benefit of those recently attracted to this board:
What are the odds that the company presenters are planning to travel to the Barcelona conference to present evidence that the drug does not work?
Recently, this board came up with about 20 plus reasons to say that the odds are "not very likely", "zilch", etc. I have been compiling all of this information that I have also published on this board. Since then, even more compelling information has been posted by others. Let's be confident in the scientific data that this board has revealed that points to Anavex being on the right track despite what Big Pharma has produced so far -- drugs that the opening speaker at the AD Conference in DC this summer said "do not work" (with the one slight exception, Aricept, that seems to work several times better when administered with Anavex 2-73). Again, S. Macfarlane said: "I have never seen anything like it." S. Macfarlane has been there conducting the trials day in and day out. Attempts have been made by some occasionally opportunistically short sellers, without any foundation, to say that Macfarlane is a fraud. Those attempts have failed. WolfWayne and others have published exhaustive information that points out that Macfarlane is not a fraud. Therefore, until proven wrong on November 7, I am placing my bet that the November conference will again report positive results for the Anavex trial Macfarlane is conducting with a drug that appears to work better than all the AD drugs on the market "that do not work."
